5

What is claimed is:

- A composition comprising a cell culture of immature animal cells, including liver, pancreas, gut, lung, or bone marrow cells, which contains at least a population of hepatocyte precursor cells capable of differentiating into hepatocytes.
- 2. The composition of claim 1, wherein the hepatocyte precursor cells are capable of differentiating into hepatocytes in a serum-free culture medium comprising extracellular matrix and liver stromal cells.
- 3. The composition of claim 2, wherein the extracellular matrix is formed from a material comprising collagen, fibronectin, laminin or combinations thereof.
 - 4. The composition of daying, wherein the collagen is type IV collagen.
- 5. The composition of claim 3, wherein the collagen is used alone or in combination with proteoglycans, or tissue extracts enriched in extracellular matrix materials.
- 6. The composition of claim 2, wherein the extra cellular matrix is coated upon a porous solid support.
- 7. The composition of claim 6, wherein the solid support comprises Millicell membrane support, filters, sponges, and hollow fiber systems.
- 8. The composition of claim 2, wherein the liver stromal cells are embryonic liver stromal cells.

5

112787-116 PATENT

The composition of claim 2, wherein the liver stromal cells are fetal liver stromal cells.

- 10. The composition of claim 1 which comprises a growth factor.
- 11. Genetically engancered hepatocyte precursor cells obtained by genetically engineering expanded hepatocytes precursor cells derived from culturing immature animal cells that contain at least a population of hepatocyte precursor cells capable of differentiating into hepatocytes.
- 12. The genetically engineered hepatocyte precursor cells of claim-11, wherein the hepatocyte precursor cells are differentiated into hepatocytes in a serum-free culture medium comprising extracellular matrix and liver stropal cells.
- 13. The genetically engineered hepatocyte precursor cells of claim 11, wherein the immature animal cells are selected from the group consisting of liver, pancreas, gut, lung, or bone marrow cells.
- 14. Genetically engineered hepatocyte precursor cells obtained by culturing immature animal cells including liver, pancreas, gut, lung, or bone marrow cells, that contain at least a population of hepatocyte precursor cells capable of differentiating into hepatocytes in a serum-free culture medium, that comprises extracellular matrix and liver stromal cells to provide expanded hepatocyte precursor cells and genetically engineering the expanded hepatocyte precursor cells.

5

- 15. The genetically engineered hepatocyte precursor cells of claim 14, wherein the liver stromal cells are embryonic liver stromal cells or fetal liver stromal cells.
- 16. The genetically engineered hepatocyte precursor cells of claim 11, wherein the genetic engineering comprises ex vivo genetic modification of the hepatocyte precursors.
- The genetically engineered hepatocyte precursor cells of claim 16, wherein ex vivo genetic modification comprises obtaining hepatocyte precursor cells from a human or non-human subject, genetically modifying the hepatocyte precursor and transferring the genetically modified hepatocyte precursor cells to the same or a different human or non-human subject.
- The genetically engineered hepatocyte precursor cells of claim 17, wherein said transferring comprises transplanting or grafting.
- 19. The genetically engineered hepatocyte precursor cells of claim 11, wherein genetically engineering comprises transducing hepatocyte precursor cells with a retroviral vector comprising a genetic material that encodes polypeptides or protein of interest and/or a dominant selectable marker.
- 20. The genetically engineered hepatocyte precursor cells of claim 11, wherein the genetic material is under the control of retroviral vector regulatory elements and/or regulatory elements of genes normally expressed in the liver.